Results 161 to 170 of about 692,682 (292)

SAFETY AND EFFICACY OF ACARBOSE IN COMBINATION WITH INSULIN GLARGINE IN TREATMENT OF ELDER DIABETIC PATIENTS

, 2020
Maham Tauqeer Sumbal Farooq
openalex   +1 more source

A pilot study comparing the CGM-assessed glycemic profiles of patients with type 1 diabetes on insulin degludec and insulin glargine [PDF]

, 2016
Akio Kuroda, Miho Tsuruo, Nanako Aki, Takeshi Kondo, Yukari Oguro, Motoyuki Tamaki, Ken‐ichi Aihara, Itsuro Endo, Toshio Matsumoto, Masahiro Abe, Munehide Matsuhisa   +10 more
openalex   +1 more source

Emulating a Randomized Controlled Trial of Long‐Acting Insulins and Cardiovascular Events Using Real‐World Data for Patients With Type 2 Diabetes

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 1, January 2026.
ABSTRACT Aims Randomized controlled trials (RCTs) have high internal validity but often have limited generalizability. To our knowledge, there have been no previous studies emulating RCTs using real‐world data to evaluate the risk of major adverse cardiovascular events (MACE) among patients with type 2 diabetes mellitus (T2DM) treated with long‐acting ...
Wanning Wang, Pauline Reynier, Michael Webster‐Clark, Oriana H. Y. Yu, Vanessa Brunetti, Kristian B. Filion   +5 more
wiley   +1 more source

United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes

Drug Design, Development and Therapy, 2017
Marc Rendell1,2 1The Rose Salter Medical Research Foundation, 2The Association of Diabetes Investigators, Newport Coast, CA, USA Abstract: Insulin degludec has been the product of a sophisticated and systematic biochemical engineering program which ...
Rendell M
doaj  

X-ray crystallography reveals insulin lisargine structure and mechanisms of glucose regulation

Scientific Reports
The development of effective and safe insulin analogs remains pivotal in advancing diabetes management. This study addresses the limitations of existing insulin therapies by introducing insulin lisargine, a novel long-acting insulin analog that resolves ...
Zhu Zhu, Zhiming Zheng, Han Wang, Li Wang, Qingrong Yang, Zhou Wei, Peng Wang   +6 more
doaj   +1 more source

Efficacy and safety of once‐weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta‐analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 210-220, January 2026.
Abstract Aims Once‐weekly basal insulins may offer similar or superior HbA1c reduction compared to once‐daily analogues in people with type 1 or type 2 diabetes. However, concerns about hypoglycaemia persist in individuals on multiple daily injections. This meta‐analysis (PROSPERO CRD42024606874) aimed to evaluate the efficacy and safety of once‐weekly
Ludovico Di Gioia, Sergio Di Molfetta, Irene Caruso, Mariangela Caporusso, Gian Pio Sorice, Angelo Cignarelli, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino   +9 more
wiley   +1 more source

A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa

Cost Effectiveness and Resource Allocation
Background Type 1 Diabetes Mellitus (T1DM) is a life-threatening condition that is managed with administered insulin. Intermediate- to long-acting insulin represents the basal insulin constituent of the total insulin used in treating T1DM.
Mark T. Verryn, Susan Cleary
doaj   +1 more source

Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 242-255, January 2026.
Abstract Aims To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by β‐cell function in exploratory analyses of the Soli‐D study. Materials and Methods Soli‐D was a 24‐week, multicentre, randomised, open‐label study in Chinese adults with uncontrolled type 2 ...
Weijun Gu, Xiaohong Wu, Minlu Zhang, Xinyi Wang, Qin Du, Lei Kang, Felipe Lauand, Agustina Alvarez, Yiming Mu   +8 more
wiley   +1 more source

Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies.

PLoS ONE, 2013
BackgroundPrevious observational studies have shown that insulin therapy may modify the risk of prostate cancer (PCa). However, these studies yielded controversial results.
Yan-bo Chen, Qi Chen, Zhong Wang, Juan Zhou   +3 more
doaj   +1 more source

Continuous Glucose Monitoring During Basal–Bolus Therapy Using Insulin Glargine 300 U mL−1 and Glargine 100 U mL−1 in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study [PDF]

, 2015
Hideaki Jinnouchi, Masayoshi Koyama, Atsushi Amano, Yoshinori Takahashi, Akira Yoshida, Kunio Hieshima, Seigo Sugiyama, Noboru Kurinami, Tomio Jinnouchi, R. H. A. Becker   +9 more
openalex   +1 more source